Literature DB >> 15879769

Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort.

Igor Frank1, Michael L Blute, Bradley C Leibovich, John C Cheville, Christine M Lohse, Horst Zincke.   

Abstract

PURPOSE: The primary tumor classification for renal cell carcinoma (RCC) was updated by the American Joint Committee on Cancer in 2002. To date the new classification has not been validated using an independent group of patients and, therefore, its accuracy for predicting patient outcome is unknown. In the current study we evaluated the 2002 primary tumor classification and compared its predictive ability with that of the 1997 classification.
MATERIALS AND METHODS: We studied 2,746 patients treated with radical nephrectomy or nephron sparing surgery for unilateral, sporadic RCC between 1970 and 2000. Cancer specific survival was estimated using the Kaplan-Meier method. The predictive abilities of the 1997 and 2002 classifications were compared using the concordance index.
RESULTS: There were 812 deaths from RCC a mean of 3.3 years following nephrectomy. Median followup in patients still alive at last followup was 9 years. Estimated 5-year cancer specific survival rates by the 2002 tumor classification were 97%, 87%, 71%, 53%, 44%, 37% and 20% in patients with pT1a, pT1b, pT2, pT3a, pT3b, pT3c and pT4 RCC, respectively. The concordance index for the association between the 2002 classification and death from RCC was 0.752 compared with 0.737 for the 1997 classification, indicating that the 2002 version contained more predictive ability.
CONCLUSIONS: Our data suggest that the 2002 primary tumor classification with pT1 cancers subclassified into pT1a and pT1b provides excellent stratification of patients according to cancer specific survival and it has a predictive ability that is superior to that of the 1997 classification.

Entities:  

Mesh:

Year:  2005        PMID: 15879769     DOI: 10.1097/01.ju.0000158043.94525.d6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  51 in total

Review 1.  Imaging of advanced renal cell carcinoma.

Authors:  Ullrich G Mueller-Lisse; Ulrike L Mueller-Lisse
Journal:  World J Urol       Date:  2010-05-11       Impact factor: 4.226

Review 2.  Results of kidney tumor cryoablation: renal function preservation and oncologic efficacy.

Authors:  Adam C Mues; Jaime Landman
Journal:  World J Urol       Date:  2010-04-23       Impact factor: 4.226

3.  Renal mass biopsy to guide treatment decisions for small incidental renal tumors: a cost-effectiveness analysis.

Authors:  Pari V Pandharipande; Debra A Gervais; Rebecca I Hartman; Mukesh G Harisinghani; Adam S Feldman; Peter R Mueller; G Scott Gazelle
Journal:  Radiology       Date:  2010-09       Impact factor: 11.105

4.  Radiofrequency ablation versus nephron-sparing surgery for small unilateral renal cell carcinoma: cost-effectiveness analysis.

Authors:  Pari V Pandharipande; Debra A Gervais; Peter R Mueller; Chin Hur; G Scott Gazelle
Journal:  Radiology       Date:  2008-05-05       Impact factor: 11.105

5.  Cryoablation or radiofrequency ablation of the small renal mass : a meta-analysis.

Authors:  David A Kunkle; Robert G Uzzo
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

Review 6.  Renal cell carcinoma: risk assessment and prognostic factors for newly diagnosed patients.

Authors:  Tracy M Downs; Matthew Schultzel; Helen Shi; Catherine Sanders; Zunera Tahir; Georgia Robins Sadler
Journal:  Crit Rev Oncol Hematol       Date:  2008-11-06       Impact factor: 6.312

Review 7.  Focal therapy for kidney cancer: a systematic review.

Authors:  Alexander Kutikov; David A Kunkle; Robert G Uzzo
Journal:  Curr Opin Urol       Date:  2009-03       Impact factor: 2.309

8.  Current status of ablative therapies for renal tumors.

Authors:  Adam C Mues; Jaime Landman
Journal:  Indian J Urol       Date:  2009 Oct-Dec

9.  Staging of renal cell carcinoma: Current concepts.

Authors:  John S Lam; Tobias Klatte; Alberto Breda
Journal:  Indian J Urol       Date:  2009 Oct-Dec

Review 10.  From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma.

Authors:  Androu Arsanious; Georg A Bjarnason; George M Yousef
Journal:  Mol Cancer       Date:  2009-03-17       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.